To access this material please log in or register

Register Authorize

Pharmacogenetic and clinical factors in adjusting the therapeutic dose of warfarin in patients with non-valvular atrial fibrillation

Dolgova E. L., Shvarts Yu. G.
State Budgetary Educational Institution of Higher Professional Education, “V. I. Razumovsky Saratov State Medical University” of the RF Ministry of Health Care, Bolshaya Kazachiya 112, Saratov 410012

Keywords: anticoagulants, warfarin, treatment, atrial fibrillation

DOI: 10.18087/rhj.2015.1.2054

Background. A key aspect in prevention of thromboembolic complications associated with atrial fibrillation (AF) is the use of anticoagulation therapy, specifically warfarin. Warfarin sensitivity considerably varies in different patients. Aim. To specify effects of different allele variants of genotype in combination with clinical factors on the pattern of adjusting the warfarin therapy in patients with non-valvular AF. Materials and methods. The study included patients with AF who were residents of the Saratov city. Results. Therapeutic doses of warfarin were related with GGCX и CYP2C9*2 gene polymorphisms in residents of the Saratov region. This finding is consistent with results of studies on other populations. Duration of warfarin dose adjustment significantly correlated with VKORC1, CYP4F2 and CYP2C9*3 gene polymorphisms. Furthermore, the highest significance was observed for the combination effect of gene allele variants and such clinical characteristics as history of MI, amiodarone therapy and smoking. Conclusion. In adjusting the warfarin dose, both pharmacogenetic and clinical characteristics of the patient and, most important, their combination effect, should be taken into consideration.
  1. Herman D, Locatelli I, Grabnar I et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5 (3):193–202.
  2. Scordo MG, Pengo V, Spina E et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002 Dec;72 (6):702–10.
  3. Morin S, Bodin L, Loriot MA et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther. 2004 May;75 (5):403–14.
  4. Загорская В. Л., Игнатьев И. В., Кропачева Е. С. и др. Поли­морф­ный маркер G3673A гена VKORC1 – новый генетический фактор, ассцоиированный с развитием геморрагических осложнений при применении непрямы х антикоаглуянтов. Клиническая фармакология и фармакоэкономика. 2008;1:29–33.
  5. Емельянов Н. В., Кропачева Е. С., Игнатьев И. В. и др. Поли­морфный маркер G-1639 (3673) A гена VKORC1, особенности дозирования и побочные эффекты перорального антикоагулянта аценокумарола в московской популяции пациентов с постоянной формой мерцательной аритмии. Медицинская генетика. 2009;8 (4):40–4.
  6. McDonald MG, Rieder MJ, Nakano M et al. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009 Jun;75 (6):1337–46.
  7. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 Apr 15;111 (8):4106–12.
  8. Borgiani P, Ciccacci C, Forte V et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009 Feb;10 (2):261–6.
  9. Pérez-Andreu V, Roldán V, Antón AI et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol thera­py. Blood. 2009 May 14;113 (20):4977–9.
  10. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009 Mar;5 (3):e1000433.
  11. Loebstein R, Vecsler M, Kurnik D et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther. 2005 May;77 (5):365–72.
  12. Chen LY, Eriksson N, Gwilliam R et al. Gamma-glutamyl carboxy­lase (GGCX) microsatellite and warfarin dosing. Blood. 2005 Nov 15;106 (10):3673–4.
  13. Kimura R, Miyashita K, Kokubo Y et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120 (2):181–6.
  14. Cha PC, Mushiroda T, Takahashi A et al. High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J Hum Genet. 2007;52 (10):856–64.
  15. Сычев Д. А., Михеева Ю. А., Кропачева Е. С и др. Влияние полиморфизма гена CYP2C9 на фармакокинетику и фармакодинамику варфарина у больных с постоянной формой фибрилляции предсердий. Клиническая медицина. 2007;85 (1):57–60.
  16. Загорская В. Л., Игнатьев И. В., Кропачева Е. С. и др. Поли­морфный маркер G3673A гена VKORC1 – новый генетический фактор, ассоциированный с развитием геморрагических осложнений при применении непрямых антикоагулянтов. Клиническая фармакология и фармакоэкономика. 2008;1:29–33.
  17. Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141 (2 Suppl): 7S-47S.
  18. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements – a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009 Apr;65 (4):365–75.
  19. Михеева Ю. А., Кропачева Е. С., Игнатьев И. В. и др. Полимор­физм гена цитохрома P4502C9 (CYP2C9) и безопасность терапии варфарином. Кардиология. 2008;48 (3):52–7.
Dolgova E. L., Shvarts Yu. G. Pharmacogenetic and clinical factors in adjusting the therapeutic dose of warfarin in patients with non-valvular atrial fibrillation. Russian Heart Journal. 2015;14 (1):45–49

To access this material please log in or register

Register Authorize
Ru En